The following is a summary of the Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Inventiva reported Q4 revenues of €17.5 million, a rise of 40% compared to the previous year, primarily driven by milestones achieved with its Chinese partner.

• R&D expenditure surged by 82%, reflecting the accelerated clinical development for NATiV3.

• The company experienced a net loss of €110.4 million for the year, higher than the €54.3 million loss in 2022.

• Inventiva secured approx. $39 million through equity issues, $50 million from Chinese partner and an additional $10 million from a licensing agreement with Pharma.

• The global cash position stood at €61 million at the start of the year, a decline from €88.4 million the previous year.

Business Progress:

• Inventiva successfully implemented innovations in the Phase 3 Trials design for Lanifibranor, intended for MASH/NASH patients.

• Licensing of Lanifibranor in Japan and South Korea finalized via agreement with Palace Pharma.

• Positive interim results from a Phase 2 clinical trial were announced, showing both Lanifibranor alone and in combination with NMPA induced fat redistribution from visceral to subcutaneous areas, subsequently improving insulin sensitivity.

• Following approval by Chinese and EU authorities, Phase 3 trials began in China.

• The company expects to conclude enrollment for Phase 3 NATiV3 clinical trial by the first half of the year.

• The potential for Lanifibranor to be prescribed for 30% of MASH patients was highlighted in a recent physician survey.

• The company plans to have a slight increase in R&D expense in 2024, with a decrease expected by 2025, and is considering options to secure additional funding, including potential partnerships and accessing the capital market.

More details: Inventiva IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.